SCHEMBL229497

SCHEMBL229497

O=C(O)C1(Cc2ccccc2)COCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.42
PPARA Q07869 4/20 0.42
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
NPSR1 Q6W5P4 1/20 0.37
FKBP1A P62942 1/20 0.36
HSD11B1 P28845 1/20 0.35
CYP3A4 P08684 2/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
USP2 O75604 1/20 0.33
HTT P42858 1/20 0.33
CES2 O00748 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3568563 0.90 PPARG (0.38) PPARGPPARAMEN1KMT2ANPSR1
SCHEMBL16296491 0.88 PPARG (0.36) PPARGPPARAMEN1KMT2ANPSR1
SCHEMBL7383125 0.79 PPARG (0.48) PPARGPPARAMEN1KMT2ANPSR1
SCHEMBL7383873 0.77 PPARG (0.47) PPARGPPARAMAOAMAOBALDH1A1
SCHEMBL5841607 0.75 SLC6A2 (0.39) PPARGPPARAKMT2AHSD11B1CYP3A4
SCHEMBL8315407 0.75 MAOA (0.37) MEN1KMT2ANPSR1FKBP1AMAOA
SCHEMBL10487154 0.74 MAOA (0.39) FKBP1AHSD11B1CYP3A4MAOAMAOB
SCHEMBL180960 0.74 MAOA (0.39) MEN1KMT2ANPSR1MAOAMAOB
SCHEMBL10029157 0.74 ALDH1A1 (0.42) NPSR1HSD11B1CYP3A4MAOAMAOB
SCHEMBL1007966 0.73 MAOA (0.38) MEN1KMT2ANPSR1FKBP1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0833937-A1 OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS Seprachem, Inc. (US) 1998-04-08 EP claimed
WO-1996040976-A1 OPTICAL RESOLUTION OF ALKYL 1,4-BENZODIOXAN-2-CARBOXYLATES USING ESTERASE FROM SERRATIA MARCESCENS SEPRACHEM, INC. (US) 1996-12-19 WO claimed
US-20120004208-A1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS GOBBI LUCA (CH) 2012-01-05 US disclosed
US-20110150833-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2011-06-23 US disclosed
US-20110052562-A1 BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2011-03-03 US disclosed
EP-2234618-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS The Scripps Research Institute (US) 2010-10-06 EP disclosed
EP-2234486-A1 BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS The Scripps Research Institute (US) 2010-10-06 EP disclosed
WO-2009079008-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS FENG YANGBO (US) 2009-06-25 WO disclosed
WO-2009079011-A1 BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-06-25 WO disclosed
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 EP disclosed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 EP disclosed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 WO disclosed
US-5510352-A REDUCING SIDE EFFECTS BY ADMINISTERING OPTICALLY PURE ISOMER SEPRACOR, INC. (US) 1996-04-23 US disclosed
US-5508279-A INCREASES URINE FLOW WHILE AVOIDING HYPOTENSIVE EFFECTS SEPRACOR, INC. (US) 1996-04-16 US disclosed
US-5229399-A Analgesics ADIR ET COMPAGNIE (FR) 1993-07-20 US disclosed
US-5229398-A Analgesics ADIR ET COMPAGNIE (FR) 1993-07-20 US disclosed
US-5192775-A Analgesics ADIR ET COMPAGNIE (FR) 1993-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004208-A1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HTR2A, HTR3A, HTR2C PPARG 1703/4885PPARA 2091/4885MEN1 3878/4885
US-20110052562-A1 BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS ROCK1, ROCK2, ARHGDIB PPARG 3743/4885PPARA 4580/4885MEN1 2186/4885
US-20110150833-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS ROCK1, RHOA, RHOT2 PPARG 3234/4885PPARA 3834/4885MEN1 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.